Stock rating for Voyager Therapeutics (VYGR) and stock price target for 2021. Also, a look at recent financial data and key multiples for this bargain stock.
Voyager Therapeutics (VYGR) Company Overview & Stock Price Forecast
Stock Price Target: $8.91
Quick Points
- Recent FDA clearance of a new gene therapy candidate for the treatment of Huntington’s disease
- Cash and cash equivalents $153.1 million
- $7.9 million in collaboration revenue from the Neurocrine
Earnings Yield
The current earnings yield for VYGR is 36.29%, in comparison to 2.88% for the S&P 500 and 1.34% for the 10-year treasury bond. The median earnings yield for the industry in which VYGR operates is 1.77%.
CLICK HERE to view our Current Portfolio return for VYGR.
Stock Price Target: $8.91
Recent Financial Results
- Voyager does not expect to generate any revenue from product sales anytime in the foreseeable future (reported in Q1 2021)
- The bulk of revenue will likely be generated from existing collaboration agreements (i.e. Neurocrine and any other strategic relationships)
- Total assets $237.7 million
- EBITDA $11.13 million
Company Overview
Voyager Therapeutics is a clinical-stage gene therapy company that focuses on the development of treatments for patients suffering from severe neurological diseases. The company’s lead candidate is a treatment for Parkinson’s disease. Voyager also has preclinical programs focusing on the treatment of Huntington’s disease, Alzheimer’s disease and dementia.
Voyager has collaboration agreements with the University of Massachusetts, ClearPoint Neuro, and Thermo Fisher Scientific, to support the development of its gene therapy programs. Additionally, the company has a license agreement with Neurocrine Biosciences for the research, development, and commercialization of gene therapy products.
Voyager Therapeutics was founded in 2013 and is headquartered in Cambridge, Massachusetts. The current CEO is Andre Turenne.